Nikolaos Chatzizacharias

Mr. Nikolaos Chatzizacharias


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2020 in World Journal of Gastrointestinal Pathophysiology
Verified
Journal Article
Open access
APAdithya M Pathanki
Adithya M Pathanki
JAJoseph A Attard
Joseph A Attard
EBElizabeth Bradley
Elizabeth Bradley
SPSarah Powell-Brett
Sarah Powell-Brett
BDBobby V M Dasari
Bobby V M Dasari
Nikolaos ChatzizachariasNikolaos Chatzizacharias
Nikolaos Chatzizacharias
Pancreaticoduodenectomy (PD) is the commonest procedure performed for pancreatic cancer. Pancreatic exocrine insufficiency (PEI) may be caused or exacerbated by surgery and remains underdiagnosed and undertreated. The aim of this review was to ascertain the incidence of PEI, its consequences and management in the setting of PD for indications other than chronic pancreatitis. A literature search of databases (MEDLINE, EMBASE, Cochrane and Scopus) was carried out with the MeSH terms "pancreatic exocrine insufficiency" and "Pancreaticoduodenectomy". Studies that analysed PEI and its complications in the setting of PD for malignant and benign disease were included. Studies reporting PEI in the setting of PD for chronic pancreatitis, conference abstracts and reviews were excluded. The incidence of PEI approached 100% following PD in some series. The pre-operative incidence varied depending on the characteristics of the patient cohort and it was higher (46%-93%) in series where pancreatic cancer was the predominant indication for surgery. Variability was also recorded with regards to the method used for the diagnosis and evaluation of pancreatic function and malabsorption. Pancreatic enzyme replacement therapy is the mainstay of the management. PEI is common and remains undertreated after PD. Future studies are required for the identification of a well-tolerated, reliable and reproducible diagnostic test in this setting.

1 January 2020 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
SKSivesh Kamarajah
Sivesh Kamarajah
FGFrancesco Giovinazzo
Francesco Giovinazzo
KRKeith J Roberts
Keith J Roberts
PPPankaj Punia
Pankaj Punia
RSRobert Sutcliffe
Robert Sutcliffe
BDBobby Vm Dasari
Bobby Vm Dasari
Kamarajah S, et al. Ann Hepatobiliary Pancreat Surg. 2020 Feb;24(1):6-16. https://doi.org/10.14701/ahbps.2020.24.1.6

14 May 2022 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MAMoath Alarabiyat
Moath Alarabiyat
SRSyed Soulat Raza
Syed Soulat Raza
JIJohn Isaac
John Isaac
DMDarius Mirza
Darius Mirza
RMRavi Marudanayagam
Ravi Marudanayagam
Nikolaos ChatzizachariasNikolaos Chatzizacharias
Nikolaos Chatzizacharias
Incidental gallbladder cancer diagnosis confers survival advantage irrespective of tumour stage and characteristics

1 April 2017 in Transplantation Reviews
Verified
Journal Article
Closed access
Nikolaos ChatzizachariasNikolaos Chatzizacharias
Nikolaos Chatzizacharias
MAMohamed Aly
Mohamed Aly
RPRaaj K. Praseedom
Raaj K. Praseedom

13 October 2020 in Pancreas
Verified
Journal Article
Closed access
JAJoseph A. Attard
Joseph A. Attard
AFAlexia Farrugia
Alexia Farrugia
APAdithya Pathanki
Adithya Pathanki
KRKeith J Roberts
Keith J Roberts
BDBobby Dasari
Bobby Dasari
Nikolaos ChatzizachariasNikolaos Chatzizacharias
Nikolaos Chatzizacharias
Historically, locally advanced pancreatic adenocarcinoma (LAPDAC) was considered a palliative condition. Advances in treatment have resulted in studies reporting survival after neoadjuvant treatment and surgery similar to earlier disease stages. However, there is no consensus on optimal LAPDAC management. Our aim was a systematic review of published evidence on LAPDAC treatment strategies with curative intent. Twenty-eight studies defining LAPDAC as per established criteria and reporting outcomes after neoadjuvant treatment with a view to resection were included. Primary outcomes were resection rate and proportion of curative resections. Secondary outcomes were postoperative mortality, progression-free survival, and overall survival. Neoadjuvant treatment varied significantly, most common being the combination of folinic acid, fluorouracil, irontecan, and oxaliplatin. Median percentage of patients proceeding to surgery after completion of neoadjuvant pathway was 33.5%. Median resection rate was 25%. Median R0 resection was 80% of resected patients. These outcomes ranged 0% to 100% across studies. Ninety-day postoperative mortality ranged from 0% to 5%. Median progression-free and overall survival for resected patients were 12.9 and 30 months, respectively, versus 13.2 months overall survival for unresected patients. In conclusion, although there is wide variability in reported LAPDAC resection rates post–neoadjuvant chemotherapy, retrospective data suggest that neoadjuvant treatment followed by surgery results in improved survival.

27 July 2023 in World Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
JHJames M Halle-Smith
James M Halle-Smith
SPSarah Powell-Brett
Sarah Powell-Brett
KRKeith Roberts
Keith Roberts
Nikolaos ChatzizachariasNikolaos Chatzizacharias
Nikolaos Chatzizacharias
Obstructive jaundice (OJ) is a common problem in daily clinical practice. However, completely understanding the pathophysiological changes in OJ remains a challenge for planning current and future management. The effects of OJ are widespread, affecting the biliary tree, hepatic cells, liver function, and causing systemic complications. The lack of bile in the intestine, destruction of the intestinal mucosal barrier, and increased absorption of endotoxins can lead to endotoxemia, production of proinflammatory cytokines, and induce systemic inflammatory response syndrome, ultimately leading to multiple organ dysfunction syndrome. Proper management of OJ includes adequate water supply and electrolyte replacement, nutritional support, preventive antibiotics, pain relief, and itching relief. The surgical treatment of OJ depends on the cause, location, and severity of the obstruction. Biliary drainage, surgery, and endoscopic intervention are potential treatment options depending on the patient's condition. In addition to modern medical treatments, Traditional Chinese medicine may offer therapeutic benefits for OJ. A comprehensive search was conducted on PubMed for relevant articles published up to August 1970. This review discusses in detail the pathophysiological changes associated with OJ and presents effective strategies for managing the condition.